Clinical Trial Update: Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating brodalumab (AMG 827) in rheumatoid arthritis patients with inadequate response to methotrexate has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• brodalumab (brodalumab)

Snippet

Sponsor: Amgen | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2021-12-21